Signal transduction inhibitors in treatment of myelodysplastic syndromes

miR-21 mediates hematopoietic suppression in MDS by activating TGF-  signaling

(2013) T. D. Bhagat et al.   BLOOD

Revisiting Use of Growth Factors in Myelodysplastic Syndromes

(2012) Kam Newman et al.   Asian Pacific Journal of Cancer Prevention

Can EGFR-TKIs be used in first line treatment for advanced non-small cell lung cancer based on selection according to clinical factors ? -- A literature-based meta-analysis

(2012) Chongrui Xu et al.   Journal of Hematology & Oncology

Phase 1 dose-ranging study of ezatiostat hydrochloride in combination with lenalidomide in patients with non-deletion (5q) low to intermediate-1 risk myelodysplastic syndrome (MDS)

(2012) Azra Raza et al.   Journal of Hematology & Oncology

Prediction of response to therapy with ezatiostat in lower risk myelodysplastic syndrome

(2012) Naomi Galili et al.   Journal of Hematology & Oncology

Directed therapy for patients with myelodysplastic syndromes (MDS) by suppression of cyclin D1 with ON 01910.Na

(2012) Matthew J. Olnes et al.   LEUKEMIA RESEARCH

Angiogenesis and Survival in Patients with Myelodysplastic Syndrome

(2012) Aleksandar Savic et al.   PATHOLOGY & ONCOLOGY RESEARCH

ALK1 as an emerging target for antiangiogenic therapy of cancer

(2011) S. I. Cunha et al.   BLOOD

Evi1 represses PTEN expression and activates PI3K/AKT/mTOR via interactions with polycomb proteins

(2011) A. Yoshimi et al.   BLOOD

High bone marrow angiopoietin-1 expression is an independent poor prognostic factor for survival in patients with myelodysplastic syndromes

(2011) C-L Cheng et al.   BRITISH JOURNAL OF CANCER

Lenalidomide in lower-risk myelodysplastic syndromes with karyotypes other than deletion 5q and refractory to erythropoiesis-stimulating agents

(2011) David Sibon et al.   BRITISH JOURNAL OF HAEMATOLOGY

A phase 2 randomized multicenter study of 2 extended dosing schedules of oral ezatiostat in low to intermediate-1 risk myelodysplastic syndrome

(2011) Azra Raza et al.   CANCER

The Role of Erythropoietin and Erythropoiesis-Stimulating Agents in Tumor Progression

(2011) B. D. Hedley et al.   CLINICAL CANCER RESEARCH

Protein Kinase R as Mediator of the Effects of Interferon (IFN) γ and Tumor Necrosis Factor (TNF) α on Normal and Dysplastic Hematopoiesis

(2011) Bhumika Sharma et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

A MEK Inhibitor Abrogates Myeloproliferative Disease in Kras Mutant Mice

(2011) N. Lyubynska et al.   Science Translational Medicine

A soluble activin receptor Type IIA fusion protein (ACE-011) increases bone mass via a dual anabolic-antiresorptive effect in Cynomolgus monkeys

(2010) Sutada Lotinun et al.   BONE

Reduced SMAD7 Leads to Overactivation of TGF-  Signaling in MDS that Can Be Reversed by a Specific Inhibitor of TGF-  Receptor I Kinase

(2010) L. Zhou et al.   CANCER RESEARCH

Role of plasmapheresis in the management of myeloma kidney: A systematic review

(2010) Diptesh GUPTA et al.   Hemodialysis International

IL-17-producing CD4+T cells, pro-inflammatory cytokines and apoptosis are increased in low risk myelodysplastic syndrome

(2009) Shahram Y. Kordasti et al.   BRITISH JOURNAL OF HAEMATOLOGY

Phase 1-2a multicenter dose-escalation study of ezatiostat hydrochloride liposomes for injection (Telintra(R), TLK199), a novel glutathione analog prodrug in patients with myelodysplastic syndrome

(2009) Azra Raza et al.   Journal of Hematology & Oncology

Inducible expression of EVI1 in human myeloid cells causes phenotypes consistent with its role in myelodysplastic syndromes

(2009) Torsten A. Konrad et al.   JOURNAL OF LEUKOCYTE BIOLOGY

Farnesyl transferase inhibitor (lonafarnib) in patients with myelodysplastic syndrome or secondary acute myeloid leukaemia: a phase II study

(2008) Christophe Ravoet et al.   ANNALS OF HEMATOLOGY

Inhibition of the TGF-  receptor I kinase promotes hematopoiesis in MDS

(2008) L. Zhou et al.   BLOOD

A Phase 2 Clinical Trial of Deforolimus (AP23573, MK-8669), a Novel Mammalian Target of Rapamycin Inhibitor, in Patients with Relapsed or Refractory Hematologic Malignancies

(2008) D. A. Rizzieri et al.   CLINICAL CANCER RESEARCH

On the use of lonafarnib in myelodysplastic syndrome and chronic myelomonocytic leukemia

(2008) E J Feldman et al.   LEUKEMIA

Targeting survival cascades induced by activation of Ras/Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways for effective leukemia therapy

(2008) J A McCubrey et al.   LEUKEMIA

MicroRNA miR-24 inhibits erythropoiesis by targeting activin type I receptor ALK4

(2007) Q. Wang et al.   BLOOD